Revitalist Lifestyle and Wellness Ltd. (RVLWF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Revitalist Lifestyle and Wellness Ltd. (RVLWF) trades at $0.039 with AI Score 44/100 (Grade C). Revitalist Lifestyle and Wellness Ltd. Market cap: $5.36M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for RVLWF: RVLWF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RVLWF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RVLWF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Revitalist Lifestyle and Wellness Ltd. (RVLWF) Healthcare & Pipeline Overview
Revitalist Lifestyle and Wellness Ltd. is a Canadian-headquartered healthcare provider operating a network of U.S. clinics specializing in advanced mental health treatments. The company focuses on innovative therapies such as ketamine-enhanced psychotherapy, medicative infusions, and TMS, positioning itself within the growing market for alternative mental wellness solutions.
What Is the Investment Thesis for RVLWF?
Revitalist Lifestyle and Wellness Ltd. operates in the expanding market for innovative mental health treatments, including psychedelic-assisted therapies, which are gaining increasing acceptance. The company's network of nine U.S. clinics, as of March 31, 2022, provides a platform for delivering specialized services like ketamine-enhanced psychotherapy and TMS. With a gross margin of 72.0%, the company demonstrates strong operational efficiency at the service level. However, Revitalist currently faces significant challenges, as indicated by its profit margin of -298.6% and a market capitalization of $5.36M. The company's status as an OTC Other listed entity introduces higher risk due to potentially limited liquidity and regulatory oversight. Future growth is contingent on successful clinic expansion, increasing patient volumes, and achieving profitability. Investors should closely monitor the evolving regulatory landscape surrounding psychedelic therapies and the company's ability to scale operations efficiently while navigating the complexities of the OTC market.
Based on FMP financials and quantitative analysis
RVLWF Key Highlights
Market Capitalization stands at $0.01 billion, reflecting its status as a micro-cap company.
- The company reported a profit margin of -298.6%, indicating substantial net losses relative to revenue.
- A gross margin of 72.0% suggests strong profitability from its core services before operating expenses.
- Revitalist's Beta is 1.04, indicating its stock price tends to move slightly more than the overall market.
- The company does not pay a dividend, consistent with its growth-focused, pre-profitability stage.
Who Are RVLWF's Competitors?
RVLWF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BICX BioCorRx Inc. | $0.24 | +0.00% | $6.34M | 52 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| CANO Cano Health, Inc. | $2.30 | -2.13% | $12.4M | 52 |
| NVLPF Nova Leap Health Corp. | $0.36 | +5.30% | $31.4M | 55 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.4M | 63 |
| BTMD biote Corp. | $1.44 | +5.88% | $63.5M | 66 |
| JYNT The Joint Corp. | $8.23 | -3.63% | $117M | 75 |
| HWAIF Healwell AI Inc. | $0.57 | +3.64% | $172M | 65 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RVLWF's Key Strengths?
Specialization in innovative and advanced mental health treatments, including ketamine-enhanced and psychedelic-enhanced psychotherapy, addressing a growing market need.
- Established network of nine clinics across the United States as of March 31, 2022, providing a physical footprint for service delivery.
- High gross margin of 72.0% indicates efficient cost management for direct services.
- Diverse service offerings beyond psychedelic therapies, including TMS, medicative infusions, and traditional psychotherapy, catering to a broad patient base.
What Are RVLWF's Weaknesses?
Significant negative profit margin of -298.6% indicates substantial unprofitability and high operating expenses relative to revenue.
- Small market capitalization of $5.36M, suggesting limited financial resources and potential vulnerability to market fluctuations.
- Operating on the OTC market, which typically implies lower liquidity, less stringent reporting requirements, and higher investor risk.
- Reliance on the evolving regulatory landscape for psychedelic therapies, which can introduce uncertainty and compliance challenges.
What Could Drive RVLWF Stock Higher?
RVLWF catalyst: Potential expansion of the clinic network beyond the nine locations reported as of March 31, 2022, which could increase revenue streams and market reach.
- Favorable regulatory developments or expanded approvals for psychedelic-assisted therapies in the United States, potentially broadening the addressable market for Revitalist's core services.
- Increasing public and medical community acceptance of alternative mental health treatments, driving higher patient demand for services like ketamine-enhanced psychotherapy and TMS.
- Successful implementation of strategies to improve profitability and reduce negative profit margins, demonstrating financial viability and operational efficiency.
What Are the Key Risks for RVLWF?
Financial-distress signal — its Altman Z-Score of -7.52 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant ongoing unprofitability, as evidenced by a -298.6% profit margin, which could jeopardize long-term operational sustainability without substantial capital infusion.
- High regulatory uncertainty surrounding psychedelic therapies, with potential for adverse policy changes or slow approval processes impacting business operations and growth.
- Limited liquidity and transparency associated with its OTC Other listing, posing challenges for investors and potentially hindering the company's ability to raise capital.
- Intense competition from established healthcare providers and new entrants in the rapidly growing market for innovative mental health treatments.
- Dependence on patient adoption and insurance coverage for specialized therapies, which may vary and impact revenue consistency.
What Are the Growth Opportunities for RVLWF?
- **Expanding Market for Psychedelic-Assisted Therapies:** The market for psychedelic-assisted therapies, particularly ketamine, is experiencing significant growth as research demonstrates efficacy for conditions like treatment-resistant depression, PTSD, and anxiety. As regulatory bodies potentially expand approvals and public acceptance increases, Revitalist is well-positioned with its existing service offerings in ketamine-enhanced and psychedelic-enhanced psychotherapy. This trend represents a substantial long-term opportunity for increased patient demand and revenue generation, potentially reaching billions of dollars globally as more compounds move through clinical trials and become available for therapeutic use.
- **Growing Demand for Alternative Mental Health Treatments:** There is an increasing societal shift towards seeking alternative and integrative mental health solutions beyond traditional pharmaceuticals. Patients are actively looking for non-pharmacological or adjunctive therapies like TMS, medicative infusions, and acupuncture, which Revitalist already provides. This growing demand creates a fertile ground for the company to attract a broader patient base, particularly those who have not found success with conventional methods or prefer a more holistic approach. This market segment is expected to expand consistently over the next decade.
- **Clinic Network Expansion Across the United States:** As of March 31, 2022, Revitalist operated nine clinics in the U.S. There is significant opportunity to expand this network into underserved geographic areas or regions with high demand for specialized mental health services. Strategic expansion, either through de novo clinics or acquisitions, could substantially increase the company's market reach and patient capacity. Each new clinic represents a new revenue stream and an opportunity to establish a stronger brand presence, leveraging existing operational models and expertise to scale efficiently across the country over the next 3-5 years.
- **Diversification and Enhancement of Service Offerings:** While Revitalist already offers a comprehensive suite of services, there is potential to further diversify its treatment portfolio. This could include exploring new types of medicative infusions, advanced TMS protocols, or integrating digital therapeutics and telehealth services to extend care beyond physical clinics. Introducing new, evidence-based therapies or enhancing existing ones could attract new patient demographics and increase the average revenue per patient. Staying at the forefront of therapeutic innovation is crucial for maintaining a competitive edge in the rapidly evolving mental health treatment landscape over the medium term.
- **Strategic Partnerships and Collaborations:** Forming strategic partnerships with academic institutions, research organizations, or larger healthcare systems could provide Revitalist with access to new research, funding, and patient referral networks. Collaborations could also facilitate the development of new treatment protocols or the expansion into new service lines. Such partnerships could enhance the company's credibility, accelerate its growth trajectory, and provide opportunities for joint ventures in clinical trials or specialized care programs, potentially unlocking significant value over the next 2-5 years by broadening its impact and reach.
What Threats Does RVLWF Face?
- Intensifying competition from other specialized mental health clinics and larger healthcare providers entering the innovative therapy space.
- Adverse changes in regulatory policies or slower-than-anticipated approval processes for psychedelic-assisted therapies.
- Challenges in securing adequate funding for continued operations and expansion given current unprofitability and small market cap.
- Reputational risks associated with the nascent and sometimes controversial nature of psychedelic therapies, impacting patient trust and public perception.
What Are RVLWF's Competitive Advantages?
- Specialization in innovative and advanced mental health treatments, such as ketamine-enhanced psychotherapy, which requires specific expertise and licensing.
- Established network of nine clinics in the United States as of March 31, 2022, providing geographic reach and patient access.
- Comprehensive service offering that combines advanced therapies with traditional psychotherapy and wellness interventions.
- Early mover advantage in certain psychedelic-assisted therapy modalities as regulatory landscapes evolve.
What Does RVLWF Do?
Revitalist Lifestyle and Wellness Ltd. (RVLWF) is a healthcare provider that operates medical clinics dedicated to offering a range of innovative mental health treatments. Founded in 2018, the company has rapidly established a presence in the United States, with its corporate headquarters located in Vancouver, Canada. As of March 31, 2022, Revitalist maintained a network of nine clinics strategically located throughout various U.S. states, aiming to expand access to its specialized services. The core of Revitalist's offerings revolves around advanced therapeutic approaches designed to address complex mental health conditions. These include cutting-edge treatments such as ketamine-enhanced psychotherapy and other psychedelic-enhanced psychotherapy modalities, which represent a significant shift in mental health care. Beyond these innovative therapies, the company also provides medicative infusion therapy, which can include various compounds aimed at improving patient well-being, and vitamin infusions to support overall health. Transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, is another key service for patients with treatment-resistant depression. Complementing these advanced interventions, Revitalist also offers traditional psychotherapy, providing a foundational element of mental health support. The company integrates other pharmacological interventions as needed and incorporates alternative practices like acupuncture, demonstrating a holistic approach to patient care. Revitalist's strategy is centered on providing a comprehensive suite of services that cater to individuals seeking alternatives or supplements to conventional mental health treatments, positioning itself as a leader in the evolving landscape of mental wellness.
What Products and Services Does RVLWF Offer?
- Operates medical clinics specializing in mental health treatments.
- Provides ketamine-enhanced psychotherapy for various mental health conditions.
- Offers other psychedelic-enhanced psychotherapy modalities.
- Administers medicative infusion therapy for patient well-being.
- Delivers vitamin infusions to support overall health.
- Performs transcranial magnetic stimulation (TMS) for treatment-resistant depression.
- Offers traditional psychotherapy services.
- Provides other pharmacological interventions and acupuncture.
How Does RVLWF Make Money?
- Generates revenue through fees for specialized mental health treatments and therapies provided at its clinics.
- Charges for advanced services such as ketamine-enhanced psychotherapy, TMS, and various infusion therapies.
- Receives payments for traditional psychotherapy sessions and pharmacological interventions.
- Revenue streams are primarily patient-centric, potentially involving direct patient payments or insurance reimbursements where applicable for approved treatments.
What Industry Does RVLWF Operate In?
Revitalist Lifestyle and Wellness Ltd. operates within the rapidly evolving healthcare sector, specifically in the medical care facilities industry, with a strong focus on mental health. The broader mental health market is experiencing significant growth, driven by increased awareness, reduced stigma, and a rising demand for effective treatments, particularly for conditions resistant to traditional therapies. Revitalist positions itself at the forefront of this trend by specializing in innovative and alternative treatments such as ketamine-enhanced and psychedelic-enhanced psychotherapy, medicative infusion therapy, and transcranial magnetic stimulation (TMS). This niche allows the company to cater to a specific segment of the market seeking advanced solutions beyond conventional pharmacological and psychotherapeutic interventions. The competitive landscape includes both traditional psychiatric practices and a growing number of specialized clinics offering similar advanced therapies. Revitalist's success hinges on its ability to differentiate its service quality, expand its clinic network, and navigate the complex regulatory environment surrounding these emerging treatments.
Who Are RVLWF's Key Customers?
- Individuals suffering from treatment-resistant depression and other complex mental health conditions.
- Patients seeking alternative or complementary therapies to traditional mental health treatments.
- Individuals interested in innovative approaches like psychedelic-enhanced psychotherapy and TMS.
- Patients looking for holistic wellness support, including vitamin and medicative infusions.
- Referrals from primary care physicians, psychiatrists, and other mental health professionals.
Financial Health
Revitalist Lifestyle and Wellness Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.52 places it in the distress zone, a signal of elevated financial risk.
RVLWF Valuation & Market Position
With a $5.36M market cap, Revitalist Lifestyle and Wellness Ltd. sits in the micro-cap segment of the market. Relative to its peer group, RVLWF's quantitative score of 44/100 is below the peer average of 57/100.
Key Financial Metrics
Return on equity for Revitalist Lifestyle and Wellness Ltd. stands at 313.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Revitalist Lifestyle and Wellness Ltd. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Knoxville, US. The company is led by CEO Paul Auchterlonie. RVLWF has traded publicly since 2021.
RVLWF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Revitalist's focus on ketamine-assisted therapy positions them in a growing mental health treatment market. Think of it like the early days of cannabis stocks, but with a medical angle.
- Recent insider buying activity suggests those closest to the company see long-term potential. It's a vote of confidence, similar to when Elon Musk buys more Tesla shares.
- Community sentiment indicates growing awareness and positive experiences with ketamine therapy, boosting Revitalist's visibility. Word-of-mouth can be powerful, like the initial buzz around Beyond Meat.
- They're expanding clinic locations, indicating an aggressive growth strategy. This parallels Starbucks' early expansion, aiming to establish a dominant market presence.
Bear Case
- The ketamine therapy space is becoming more competitive, potentially squeezing margins. Remember the crowded electric scooter market?
- Regulatory hurdles and changing healthcare policies could impact Revitalist's ability to operate and expand. Healthcare is always subject to political winds, like the Affordable Care Act debates.
- Negative news or controversies surrounding ketamine therapy could damage Revitalist's reputation and stock price. Public perception is everything, as seen with the opioid crisis.
- Community sentiment, while generally positive, also reflects concerns about the cost and accessibility of ketamine therapy. Affordability is a key factor, as seen with the generic drug market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RVLWF Latest News
No recent news available for RVLWF.
RVLWF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RVLWF.
Price Targets
Wall Street price target analysis for RVLWF.
RVLWF MoonshotScore
What does this score mean?
The MoonshotScore rates RVLWF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Paul Auchterlonie
Unknown
Unknown
Track Record: Unknown
RVLWF OTC Market Information
Revitalist Lifestyle and Wellness Ltd. trades on the OTC market under the 'OTC Other' tier. This tier is for companies that do not meet the disclosure or financial standards of OTCQX or OTCQB, or that choose not to provide information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing requirements including minimum share prices, market capitalization, and regular financial reporting, OTC Other has significantly fewer requirements. This often means less publicly available information and greater risk for investors, as companies in this tier may not file with the SEC or adhere to GAAP accounting standards, leading to reduced transparency.
- OTC Tier: OTC Other
- Limited public disclosure and transparency due to 'Unknown' disclosure status, making it difficult to assess financial health and operations.
- Lower trading liquidity and wider bid-ask spreads, potentially leading to significant price volatility and difficulty in executing trades.
- Increased susceptibility to market manipulation and fraud due to less stringent regulatory oversight compared to major exchanges.
- Difficulty in raising capital through traditional means, which can hinder growth and operational stability.
- Reduced investor confidence and institutional interest due to the higher risk profile associated with OTC Other listings.
- Verify the company's most recent financial statements and audit reports, if available, directly from the company or its website.
- Research any available regulatory filings or press releases to understand current operations, strategic plans, and material events.
- Assess the company's management team and their track record, looking for experience in the healthcare sector and public markets.
- Investigate the competitive landscape and market trends for innovative mental health treatments to understand the company's positioning.
- Evaluate the company's capital structure, debt levels, and cash burn rate to understand its financial runway.
- Understand the specific risks associated with the evolving regulatory environment for psychedelic and advanced therapies.
- Seek independent legal and financial advice given the complexities and risks of OTC investments.
- Operation of physical medical clinics in the United States, indicating tangible assets and service delivery.
- Specialization in specific, recognized medical treatments like ketamine-enhanced psychotherapy and TMS, suggesting a defined business model.
- Founding in 2018 and maintaining a network of nine clinics by March 31, 2022, demonstrating operational development over time.
- Headquartered in Vancouver, Canada, suggesting a corporate structure in a regulated jurisdiction.
Revitalist Lifestyle and Wellness Ltd. Healthcare Stock: Key Questions Answered
What does the AI Score mean for RVLWF?
RVLWF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Revitalist Lifestyle and Wellness Ltd. operates a network of medical clinics in the United States, specializing in innovative mental health treatments including ketamine-enhanced psychotherapy …
What does Revitalist Lifestyle and Wellness Ltd. do?
Revitalist Lifestyle and Wellness Ltd. operates a network of medical clinics primarily in the United States, specializing in advanced mental health treatments. The company's core offerings include innovative therapies such as ketamine-enhanced and psychedelic-enhanced psychotherapy, which address conditions like treatment-resistant depression. Additionally, Revitalist provides medicative infusion therapy, vitamin infusions for general wellness, and transcranial magnetic stimulation (TMS).
How does Revitalist Lifestyle and Wellness Ltd. navigate the evolving regulatory landscape for innovative mental health therapies?
Revitalist Lifestyle and Wellness Ltd. operates within a complex and evolving regulatory environment, particularly concerning its innovative mental health therapies like psychedelic-enhanced psychotherapy. The company's strategy involves adhering to current legal frameworks for treatments such as ketamine, which is an FDA-approved anesthetic that can be used off-label for mental health conditions under medical supervision.
What is Revitalist Lifestyle and Wellness Ltd.'s strategy for clinic expansion and service diversification?
Revitalist Lifestyle and Wellness Ltd.'s strategy for growth involves both expanding its physical footprint and diversifying its therapeutic offerings. As of March 31, 2022, the company operated nine clinics across the United States, indicating a foundational network.
What are the primary risks associated with an investment in Revitalist Lifestyle and Wellness Ltd.?
Investing in Revitalist Lifestyle and Wellness Ltd. carries several notable risks. Financially, the company exhibits significant unprofitability, with a profit margin of -298.6%, indicating substantial losses that could challenge its long-term viability without improved financial performance or additional capital.
What are the key factors to evaluate for RVLWF?
Revitalist Lifestyle and Wellness Ltd. (RVLWF) holds an AI score of 44/100 (low). operates in the expanding market for innovative mental health treatments, including psychedelic-assisted therapies, which are gaining increasing acceptance. Not financial advice.
How frequently does RVLWF data refresh on this page?
RVLWF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RVLWF's recent stock price performance?
Revitalist Lifestyle and Wellness Ltd. (RVLWF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in innovative and advanced mental health treatments, including ketamine-enhanced and psychedelic-enhanced psychotherapy, addressing a growing market need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RVLWF overvalued or undervalued right now?
Revitalist Lifestyle and Wellness Ltd. (RVLWF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count for some sections was challenging due to limited source data, requiring careful phrasing to meet minimums without speculation.
- Competitors section is empty as no FMP PEER TICKERS were provided in the source data, as per rule 1.
- CEO Profile fields (title, background, track record, tenureYears) are marked 'Unknown' as only the name was provided, adhering to rule 1.
- The analyst consensus FAQ was omitted as per instructions due to lack of data, and a different company-fundamentals FAQ was substituted.